OMNICELL, INC. Q3 FY2025 earnings call

• Strong quarter with total revenues, non-GAAP EBITDA, and non-GAAP EPS exceeding upper end of previously issued guidance.
• Strength in core point-of-care business, with continued demand for flagship point-of-care connected devices like XTExtend.
• Progress in transformation to an intelligence medication management technology company, with positive customer feedback on OmniSphere cloud-based platform.
• Focus on 3 core growth pillars: expanding market presence, accelerating OmniSphere platform, and operational excellence.
• Welcome of Baird Radford as new Executive Vice President and Chief Financial Officer.
• Customer wins and increased platform adoption in inpatient and outpatient settings, including with major health systems and government facilities.
• Specialty Pharmacy Services offering gaining traction, with new program launches and expansions.

Total revenue in the third quarter was $311 million, an increase of $28 million (10%) compared to Q3 2024 and $20 million (7%) compared to the previous quarter. Product revenue in Q3 2025 was $177 million, an increase of $19 million compared to Q3 2024 and $14 million compared to the previous quarter. Service revenue in Q3 2025 was $133 million, an increase of $9 million compared to Q3 2024 and $6 million compared to the previous quarter. Non-GAAP gross margin for Q3 2025 was 44.2%, compared to 44.5% in Q3 2024 and 44.7% in the prior quarter.

• Fourth quarter 2025 total revenues expected to be between $306 million and $316 million, product revenues between $175 million and $180 million, service revenues between $131 million and $136 million.
• Full year 2025 total revenues now expected to be in the range of $1.177 billion to $1.187 billion (previously $1.13 billion to $1.16 billion).
• Product revenues for full year 2025 now expected to be in the range of $661 million to $666 million (previously $625 million to $640 million).
• Service revenue: Technical Services revenue midpoint increased to $260 million, while SaaS and expert services revenue midpoint lowered to $259 million.
• Non-GAAP EBITDA for full year 2025 expected to be in the range of $140 million to $146 million (previously $130 million to $145 million).
• Non-GAAP EPS for full year 2025 expected to be in the range of $1.63 to $1.73 (previously $1.40 to $1.65).

• Tariffs impacted profitability by approximately $6 million net in Q3 2025, expected to have similar impact in Q4 2025, with full year 2025 net impact projected at ~$15 million.
• Supply chain challenges and regulatory uncertainties related to product development and deployment.
• Headwinds in SaaS and expert services revenue growth, particularly in EnlivenHealth within the retail pharmacy space.

Q: Jessica Tassan asked about engaging with start-ups for robotics and smaller versions of central dispensing robots, and clarification on OmniSphere.

A: Randall Lipps mentioned hiring Perry Genova with robotic background, and OmniSphere runs on current products with early adopters, and smaller robots and different dynamics are being considered.

Q: Matthew Hewitt asked about IV opportunity and hub-and-spoke model.

A: Randall Lipps said they see opportunity in IV space with different solutions depending on health system size and goals.

Q: Stan Berenshteyn asked about bookings guidance and compounding robot update.

A: Randall Lipps said bookings engagement is strong with no change in product mix, and compounding robot is in limited release with semi-automated platform doing well.

Q: David Larsen asked about buying environment and GLP-1s.

A: Randall Lipps said things are improving with hospital system specifics, and refresh cycle approaching provides opportunity for Omnicell's platforms.

Q: William Sutherland asked about EnlivenHealth headwinds and capital deployment.

A: H. Radford said no major headwinds seen, and Randall Lipps mentioned completing share repurchase and being prudent in capital deployment.

Q: Scott Schoenhaus asked about 340B and customer behavior.

A: Randall Lipps said more crossover sales from current customers, positive results, and 340B business is positive.

Q: Eugene Mannheimer asked about point-of-care business outperformance and XT upgrade.

A: H. Radford said consistency in wins and expansions, and Randall Lipps and Kathleen Nemeth discussed early stages of XT upgrade.

Q: Allen Lutz asked about competitor system sunsetting and market share opportunity.

A: Randall Lipps said it's a significant market, OmniSphere provides flexibility, and they believe in capturing fair share.